DEF 14A: STERIS plc Sets Date for 2024 Annual General Meeting, Outlines Key Proposals

STERIS plc will hold its Annual General Meeting on August 1, 2024, in Dublin, Ireland, with shareholders voting on director elections, auditor ratification, executive compensation, and share issuance authorizations.

Summary

• STERIS plc will hold its 2024 Annual General Meeting on August 1, 2024, in Dublin, Ireland.
• Shareholders will vote on several key proposals, including the re-election of ten directors.
• They will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending March 31, 2025.
• Additionally, shareholders will vote on the appointment and remuneration of Ernst & Young Chartered Accountants as the company's Irish statutory auditor.
• An advisory vote on the compensation of the company's named executive officers is also scheduled.
• Shareholders will consider renewing the Board's authority to issue shares and opt-out of statutory pre-emption rights under Irish law.
• The Board of Directors recommends voting FOR all resolutions for proposals 1 through 7.
• The record date for determining shareholders eligible to vote at the Annual Meeting is June 3, 2024.
• Proxy votes must be received no later than 4:59 a.m. Dublin Time on Wednesday, July 31, 2024.

Sentiment

Score: 7

Explanation: The document is factual and positive, outlining growth and strategic decisions. The Board's recommendations and the high percentage of shareholder support in previous votes suggest confidence in the company's direction.

Positives

• The Board of Directors is recommending shareholders vote FOR all resolutions for proposals 1 through 7.
• The company is providing multiple methods for shareholders to vote, including internet, telephone, and mail.
• The company is providing access to proxy materials through the internet, reducing printing and postage costs.

Future Outlook

Several strategic decisions were made in fiscal 2024 that should position STERIS for future growth, including the initiation of a targeted restructuring plan and the announcement of a divestiture of the Dental segment.

Management Comments

• The Board of Directors has determined that resolutions for proposals 1 through 7 to be voted upon at the meeting are in the best interests of the company and its shareholders as a whole.
• The Board of Directors unanimously recommends that you vote FOR for all resolutions for proposals 1 through 7.

Industry Context

The document provides insight into STERIS's governance practices, aligning with requirements for public companies incorporated in Ireland and listed on U.S. markets, and its compensation strategies within the healthcare industry.

Comparison to Industry Standards

• The company benchmarks executive compensation against a peer group including Agilent Technology, Baxter International, Boston Scientific, and others.
• The company targets base salaries, cash bonuses and equity compensation within a general range of 15% above or below the market median of those components.
• The company's peer group for fiscal 2024 included companies with revenue between approximately $1.5 billion and $14.0 billion, market capitalization between approximately $6.5 billion and $60.0 billion, and employees between 6,800 and 60,000.

Stakeholder Impact

• Shareholders are being asked to vote on matters that will impact the company's governance and financial performance.
• Employees are impacted by the company's compensation policies and benefit programs.
• Customers may be impacted by the company's strategic decisions and future growth.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The results of the polls taken on the resolutions at the Annual Meeting will be made available on the Company's website and filed with the SEC.

Key Dates

Keywords

Annual General Meeting, Proxy Statement, STERIS plc, Shareholders, Directors, Auditor, Executive Compensation, Share Issuance, Pre-emption Rights, Governance